COPD

Antiplatelet Therapy in COPD May Reduce All-Cause Mortality, Improve Quality of Life

By

Amit Akirov, MD

Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.

Assessing Exercise Techniques in Pulmonary Rehabilitation for COPD

By

Tori Rodriguez, MA, LPC, AHC

Pulmonary rehabilitation programs represent a key component in the management of patients with chronic obstructive pulmonary disease.

COPD-Related Cognitive Impairment Unlike Other Forms of Dementia

By

Tori Rodriguez, MA, LPC, AHC

The prevalence of cognitive impairment is higher in patients with COPD compared with healthy individuals.

Major Airway Gel-Forming Mucin MUC5AC May Serve as COPD Biomarker

By

Rita Aghjayan

An increased concentration of MUC5AC in the airways of lungs may play an important pathobiological role in the initiation and progression of COPD.

Preoperative LAMA/LABA Reduces Surgical Complications in Lung Cancer With COPD

By

Brandon May

Preoperative use of a LAMA with a LABA was associated with significant improvements in lung function compared with use of LAMA alone in patients with lung cancer and COPD.

Utility of Clinically Important Deterioration in Diverse Populations With COPD

By

Rita Aghjayan

Using clinically important deterioration as a composite endpoint for disease progression may be beneficial in predicting long-term clinical outcomes in Japanese patients with COPD.

Metformin May Slow Emphysema Progression, Systemic Consequences

By

Virginia A. Schad, PharmD, RPh

Metformin has demonstrated potential for slowing emphysema progression and its systemic consequences.

Enhanced Pulmonary Rehabilitation Program May Reduce Physician Visits in COPD

By

Virginia A. Schad, PharmD, RPh

In patients with COPD, an enhanced pulmonary rehabilitation program that emphasizes chronic disease self-management may help to reduce physician visits.